Operating Regions in Cooling Cocrystallization of Caffeine and Glutaric Acid in Acetonitrile

Yu, Zai Qun; Chow, Pui Shan; Tan, Reginald B. H.

doi:10.1021/cg100198u

Cited by 84 publications

(95 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liquid-assisted grinding Gliclazide 92 Sebacic acid, α-hydroxyacetic acid Entacapone 93 Theophylline, nicotinamide, Acetamide isonicotinamide, pyrazinamide, isoniazid 99 Vanillic acid, ferulic acid, caffeic acid, resorcinol…”

Section: Ethical Issues Not Applicablementioning

confidence: 99%

Pharmaceutical Co-Crystallization: Regulatory Aspects, Design, Characterization, and Applications

et al. 2020

View full text Add to dashboard Cite

Pharmaceutical co-crystals are novel class of pharmaceutical substances, which possess an apparent probability of advancement of polished physical properties offering stable and patentable solid forms. These multi-component crystalline forms influence pertinent physicochemical parameters like solubility, dissolution rate, chemical stability, physical stability, etc. which in turn result in the materials with superior properties to those of the free drug. Co-crystallization is a process by which the molecular interactions can be altered to optimize the drug properties. Co-crystals comprise a multicomponent system of active pharmaceutical ingredient (API) with a stoichiometric amount of a pharmaceutically acceptable coformer incorporated in the crystal lattice. By manufacturing pharmaceutical co-crystals, the physicochemical properties of a drug can be improved thus multicomponent crystalline materials have received renewed interest in the current scenario due to the easy administration in the pharmaceutical industry. There is an immense amount of literature available on co-crystals. However, there is a lack of an exhaustive review on a selection of coformers and regulations on co-crystals. The review has made an attempt to bridge this gap. The review also describes the methods used to prepare co-crystals with their characterization. Brief description on the pharmaceutical applications of co-crystals has also been incorporated here. Efforts are made to include reported works on co-crystals, which further help to understand the concept of co-crystals in depth.

show abstract

Section: Ethical Issues Not Applicablementioning

confidence: 99%

Pharmaceutical Co-Crystallization: Regulatory Aspects, Design, Characterization, and Applications

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Although there is no chemical reaction, this method is conceptually close to precipitation, because it is the addition of a foreign species, which triggers crystallization. When the operation is carried out in polythermal mode, this region is narrower [109,110]. Another advantage of this method is that it is possible to increase the yield either by adjusting the amount of co-crystallizing agent introduced in the medium [14,109] or by finishing the operation with a classic cooling crystallization (if the solubility product declines with temperature).…”

Section: Co-crystallizationmentioning

confidence: 99%

Crystallization of Pharmaceutical Crystals

Veesler

Puel

2015

Handbook of Crystal Growth

View full text Add to dashboard Cite

“…Measuring the concentration changes of the two drug substances, it was hence possible to determine how much of the two crystalline phases was formed. Furthermore, the use of ATR-FTIR spectroscopy allows determining complete temperature-dependent phase diagrams for solute/solute/solvent systems, as was shown for the co-crystallization of caffeine and glutaric acid from acetonitrile (Yu, Chow, and Tan, 2010). The knowledge of such a complete phase diagram allows defining safe operating regions where the co-crystal is consistently produced with high purity.…”

Section: Co-crystal Formationmentioning

confidence: 99%